Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JPX, also known as "JPX transcript, XIST activator (non-protein coding)", is a long non-coding RNA (lncRNA) located within the X-inactivation center (XIC) and functions as a key activator of XIST, the master regulator of X chromosome inactivation (XCI)[1][2][3]. JPX promotes XIST expression by interacting with architectural proteins such as CTCF, evicting repressors from the XIST promoter, and thus enabling chromosome-wide gene silencing in females[1][2]. JPX acts through both cis (local) and trans (distal) mechanisms to regulate XIST expression, and its transcript levels are critical for proper XCI[1][3]. In cancer contexts, JPX is frequently overexpressed and can act as an oncogenic factor by functioning as a competing endogenous RNA, sequestering specific microRNAs that regulate cell proliferation and invasion[2]. JPX does not code for a protein and is not a classical therapeutic target such as a receptor or enzyme, but plays a critical role in gene regulation and is implicated as a potential biomarker in oncology and developmental biology[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JPX transcript, XIST activator (non-protein coding) (JPX).